Email this article 
Pathogenesis and therapy of anemia in oncohemathology patients with recombinant erythropoietin agents (review)
- Authors: Romanenko N.A.1
-
Affiliations:
- Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑biological Agency
- Issue: Vol 7, No 3 (2012)
- Pages: 22-29
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 22.08.2012
- URL: https://oncohematology.abvpress.ru/ongm/article/view/50
- DOI: https://doi.org/10.17650/1818-8346-2012-7-3-22-29
- ID: 50
Cite item
Full Text
Abstract
The article presents a literature review on the mechanisms of anemia in patients with hematologic malignancies and a classification of chronic anemia and methods of its correction. It describes in detail the mechanism of action, indications and side effects of rembinant erythropoietin (rEPO). It gives anemia treatment algorithms with rEPO in patients with chronic blood malignancies. The analysis of rEPO efficacy is shown in anemia treatment in patients with various types of cancer. It presents the recommendations of ASCO/ASH for the use of rEPO in various patients categories.
About the authors
N. A. Romanenko
Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico‑biological Agency
Author for correspondence.
Email: rom-nik@yandex.ru
Russian Federation
References
Supplementary files
